Join the Oncology Voice Network. Join for Free
MSL Visibility - How to SUCCEED in 2024
Medical Science Liaisons MSL effectiveness MSL visibility MSL strategies Eleonora Goldberg

MSL Visibility - How to SUCCEED in 2024


Share This Article


Summary

Tom Caravela welcomes Eleonora Goldberg to explore the evolving role of Medical Science Liaisons (MSLs) within organizations. They delve into the key attributes leaders seek in MSLs and share strategies for standing out and enhancing team performance. Essential skills for MSL effectiveness and methods for evaluating performance are discussed, alongside preparing for industry changes and maintaining positivity in 2024. Eleonora offers predictions and expresses optimism for the future of MSLs. The episode concludes with closing remarks, appreciation, and a reminder to subscribe and stay engaged.

My guest this week is Eleonora Goldberg, Vice President, Medical Affairs at Arrowhead Pharmaceuticals and we discuss MSL Visibility and how to succeed in 2024.

 Eleonora shares….

👉 What is the VALUE of MSLs
👉 What leaders look for in MSLs
👉 How can MSLs separate themselves from their peers
👉 How might 2024 be different for MSLs
👉 What advice is there for dealing with uncertainty

Click for Source
Medical Science Liaisons, MSL effectiveness, MSL visibility, MSL strategies, Eleonora Goldberg

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
How to Start Presenting Like a Pro
Partner Avatar MSL Talk: Tom Caravela

How to Start Presenting Like a Pro

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Explore OVN